Please login to the form below

Baxalta

This page shows the latest Baxalta news and features for those working in and with pharma, biotech and healthcare.

Immunology keeps Shire figures solid as Takeda takeover nears

$612m but the company’s haematology franchise – including haemophilia products acquired along with Baxalta in 2016 – down 1% to $951m.

Latest news

Sanofi’s rare blood disorder drug Cablivi set for European approval

Shire unit Baxalta got a green light for Veyvondi (vonicog alfa) for the treatment of von Willebrand disease, the most common inherited bleeding disorder.
Freeline raises £88m to accelerate haemophilia gene therapy

Freeline’s chief executive Anne Prener – who joined the company last July and previously led Baxalta’s haematology programmes – says the cash injection would also be used to beef up its ... Following after is Sangamo with SB-FIX in phase I/II
Shire warms to Takeda’s latest offer, extending deadline

its $32bn takeover of Baxalta two years ago.
Shire rebuffs Takeda bids, as Allergan bows out

Shire was recently tipped as the next big pharma takeover, in part because of pipeline troubles and its share price has been depressed following its $36bn takeover of Baxalta in 2016,
Shire offloads oncology unit to Servier for $2.4bn

Oncaspar and the other cancer assets were acquired by Shire as part of its takeover of Baxalta in 2016, and contributed $262m out of total group sales of $14.5bn last

More from news
Approximately 16 fully matching, plus 33 partially matching documents found.

Latest Intelligence

Deal Watch January 2018

quite as fast as Shire's move to take over Baxalta when it was spun out of Baxter in July 2015).
The good, the bad and the ugly

Shire’s incredible revenue growth of almost 57%, helped by its $32bn acquisition of Baxalta in 2016, lifted it into the top 20 for the first time in its history. ... However, investors fear that challenges in the $11bn haemophilia market could lead to
Deal Watch January 2017

Interestingly 2016 had opened with Shire's announcement that the Baxalta acquisition was going ahead resulting in one of the year's biggest headlines with its final value of £32bn.
A rare talent

The biggest of these moves was its $32bn acquisition of Baxalta, which was officially completed in June last year and elevated its position in orphan drugs, which it expects to account ... The combination of Shire and Baxalta was extremely transformative,
Deal Watch December 2016

In terms of headline figures (33 of the 39 deals announced financials) December came in at $29bn, second only to January 2016 at $42bn (which included the $32bn Shire-Baxalta deal). ... Excluding the Shire-Baxalta and Pfizer-Medivation deals, the figure

More from intelligence
Approximately 1 fully matching, plus 13 partially matching documents found.

Latest appointments

New hires at Bristol-Myers Squibb, Acceleron and FerGene

Prior to Ipsen, he held a number of leadership roles, including executive vice president and president of oncology at Baxalta, and chief commercial officer of Endocyte.
Dr Sotirios Stergiopoulos leaves Shire for Ipsen

He first joined the French biopharma firm from Baxalta - now Shire - last year, where he served as vice president, head of global medical affairs oncology.
AVEO appoints Nikhil Mehta as its senior VP, regulatory and quality assurance

Prior to Tang Capital, he served as global head of regulatory affairs at Baxalta and before that, he was vice president, global regulatory affairs, oncology, haematology, immunology and diagnostics at Merck
Shire promotes Joanne Cordeiro to chief human resources officer

Dr Flemming Ornskov, Shire's chief executive officer, said: “Joanne’s dedication, skill, and expertise have been an invaluable resource in the successful integration of Baxalta into the Shire business.
Anne Prener to lead Freeline Therapeutics

Prior to Gyroscope, Frener served as vice president, clinical research haematology and global therapeutic area head of haematology at Baxalta.

More from appointments
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest from PMHub

Mergers and acquisitions: agents for change

serial shakeups such as seen for Baxter-Baxalta-Shire-Takeda, these events transform the industry landscape, reshaping pipelines and reshuffling R&D priorities.
Bedrock Healthcare Communications

Abbvie. Baxalta. Baxter. Biogen. BMS. Britannia. CareFusion. Celgene. Ipsen. Janssen. Novartis.

More from PMHub
Approximately 1 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Omnichannel Account Director: £55,000 - £65,000 yearly

Senior Medical Writer: Highly competitive salary

Pharmacovigilance Manager: Highly competitive salary

Strategy Director - Healthcare Advertising: Highly competitive salary

Technical Sales Representative: Highly competitive salary

Associate Director - Global Healthcare Consulting: Highly competitive salary

Early Access Program - Regulatory Affairs (EAP-RA): Highly competitive salary

Pharmacovigilance Project Lead: Highly competitive salary

PMHub

Add my company

AMICULUM

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >300 healthcare communications professionals,...

Latest intelligence

Improving cardiovascular disease care and awareness: Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...
Virtual Patient Engagement Program: A Customer Story: Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
Humancomms for humancare?: Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...

Email:
Password:

Please login to the form below

Baxalta

Subscribe to our email news alerts

Quick links